"A drug potent enough to cause artificial hibernation". Discovery of chlorpromazine changed psychiatry
Ajanki, T.; Laborit, H.
Lakartidningen 102(3): 144-145
2005
ISSN/ISBN: 0023-7205 PMID: 15712740 Document Number: 591352
Document emailed within 1 workday
Related Documents
Kojima, H.; Okabe, T.; Nagano, T. 2013: Open innovation center for drug discovery: a research-supporting network for drug discovery Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 327-332Fujita, Y. 2013: Innovation by TaNeDS (Take a New challenge of Drug diScovery) collaborative drug discovery project Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(2): 89-95
Baev, B.; Lazareva, Z.; Koshev, L. 1973: Severe postoperative thyrotoxic attack treated by artificial hibernation Khirurgiia 26(6): 494-497
Ogata, N.; Narahashi, T. 1990: Potent blocking action of chlorpromazine on two types of calcium channels in cultured neuroblastoma cells Journal of Pharmacology and Experimental Therapeutics 252(3): 1142-1149
Shcherbak, L.F. 1980: Activity of certain dehydrogenases in the denervated skeletal muscles of susliks during hibernation and artificial hypothermia Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 3: 44-46
Shen, Y. 2007: Discovery on Target 2007--CHI's Fifth Annual Conference. RNAi for Drug Discovery and Therapeutics IDrugs: the investigational drugs journal 10(12): 848-850
Young, S.S. 1999: Discovery 99: accelerate and improve the drug discovery process. 26-29 April 1999, San Diego, CA, USA IDrugs: the investigational drugs journal 2(7): 648-649
Frye, S.V.; Bramson, H.N.; Hermann, D.J.; Lee, F.W.; Sinhababu, A.K.; Tian, G. 1998: Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase Pharmaceutical Biotechnology 11: 393-422
Aarthy, M.; Singh, S.Kumar. 2018: Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach Current Topics in Medicinal Chemistry 18(18): 1585-1602
Brenner, P.; Spitzer, R. 2014: The diagnosis coup that changed psychiatry. the story of Robert Spitzer and the advent of DSM-IIi Lakartidningen 111(42): 1851-1852
Adkison, K.K.; Halm, K.A.; Shaffer, J.E.; Drewry, D.; Sinhababu, A.K.; Berman, J. 1998: Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters Pharmaceutical Biotechnology 11: 423-443
Mollison, K.W.; Fey, T.A.; Gauvin, D.M.; Sheets, M.P.; Smith, M.L.; Pong, M.; Krause, R.; Miller, L.; Or, Y.S.; Kawai, M.; Wagner, R.; Wiedeman, P.E.; Clark, R.F.; Gunawardana, I.W.; Rhoades, T.A.; Henry, C.L.; Tu, N.P.; BaMaung, N.Y.; Kopecka, H.; Liu, L.; Xie, Q.; Lane, B.C.; Trevillyan, J.M.; Marsh, K.; Luly, J.R. 1998: Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases Current Pharmaceutical Design 4(5): 367-379
Crowley, J.J.; Sullivan, P.F.; McLeod, H.L. 2008: Untapped resources for pharmacogenomic discovery in psychiatry Current Opinion in Molecular Therapeutics 10(3): 205-206
Van Heek, M.; France, C.F.; Compton, D.S.; McLeod, R.L.; Yumibe, N.P.; Alton, K.B.; Sybertz, E.J.; Davis, H.R. 1997: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 Journal of Pharmacology and Experimental Therapeutics 283(1): 157-163
Blondelle, S.E.; Crooks, E.; Ostresh, J.M.; Houghten, R.A. 1999: Mixture-based heterocyclic combinatorial positional scanning libraries: discovery of bicyclic guanidines having potent antifungal activities against Candida albicans and Cryptococcus neoformans Antimicrobial Agents and ChemoTherapy 43(1): 106-114
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Kashyap, A.; Singh, P.Kumar.; Silakari, O. 2018: Counting on Fragment Based Drug Design Approach for Drug Discovery Current Topics in Medicinal Chemistry 18(27): 2284-2293
Emilien, G.; Maloteaux, J.M. 1998: Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities International Journal of Clinical Pharmacology and Therapeutics 36(4): 181-194
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598
Bittner, B.; Mountfield, R.J. 2002: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters Current Opinion in Drug Discovery and Development 5(1): 59-71